FIELD: biotechnology.
SUBSTANCE: invention refers to production of means containing at least one polypeptide selected from SEQ ID NO: 4, 2, 8, 10 and 12, and/or recombinant vector(s), comprising polynucleotide(s) encoding at least one polypeptide, as the active ingredient(s), and can be used in medicine. The resulting means is used for efficient induction of T-cell immunity against malignancies expressing KATNAL1.
EFFECT: invention allows to obtain antigen-presenting cells presenting the polypeptide obtained from KATNAL1, and to effectively induce cytotoxic cells against KATNAL1, which is efficient as a therapeutic agent against malignant neoplasms expressing KATNAL1.
7 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNITY-INDUCING AGENT | 2012 |
|
RU2634862C2 |
| IMMUNITY INDUCING AGENT | 2009 |
|
RU2511039C2 |
| IMMUNITY INDUCING AGENT | 2013 |
|
RU2639518C2 |
| IMMUNE-INDUCING AGENT | 2017 |
|
RU2733841C2 |
| MEDICATION FOR IMMUNITY INDUCTION AND METHOD OF MALIGNANT TUMOUR IDENTIFICATION | 2009 |
|
RU2519675C2 |
| SPARC-DERIVATIVE ANTIGENIC PEPTIDES CAUSING TUMOUR REJECTION AND MEDICATIONS CONTAINING SUCH PEPTIDES | 2007 |
|
RU2451521C2 |
| IMMUNITY INDUCER | 2017 |
|
RU2755542C2 |
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| CDCA1 EPITOPE PEPTIDES AND VACCINES CONTAINING SAME | 2009 |
|
RU2502740C2 |
| CDCA1 PEPTIDE AND PHARMACEUTICAL DRUG CONTAINING IT | 2008 |
|
RU2486195C2 |
